MI Dendream retweeted
$NWBO DCVAX needs to be front and center option for the patients, I did read the story of Laura Nuttall who finally opted for DCVAX after researching but unfortunately not enough of the tumor was saved for the Vaccine Treatment. Doctors should be well informed about DCVAX and at least provide the details and options for the patient and especially ensuring the correct procedures are in place for obtaining the tumor tissue and preserving properly for the Vaccine. ourbrainbank.org/laura/
"Right from the beginning we looked to find other options that might be available. From our own research, we knew that we needed to save the tumour tissue for future immunotherapy purposes. However, tumours can be diffuse and not especially solid on removal and the most important task for the surgeon is the safe removal of the tumour and subsequent pressure in the brain rather than the storage of any removed matter.
We struggled to find the right person to talk to about the stored tumour tissue, nobody seemed to know who we should talk to, and we were bounced around looking for the right person to help us, hitting brick walls on a daily basis. Members of the public are not encouraged to contact the pathology labs but neither the surgeon nor the oncologist seemed to have the information we needed.
We had decided to explore a form of vaccine immunotherapy (DCVax) with a company called Northwest Bio and our oncologist had assured us that he’d been told there was plenty of tissue frozen and available to use for this purpose. However, when their laboratory began the process of producing the lysate to make the vaccine, there was nowhere near enough, just the tiniest sliver. We’d fundraised the money required to produce the vaccine, but the treatment wasn’t possible because we just didn’t have the tumour tissue, this was utterly devastating."
Their is numerous successfull stories of DCVAX for the past decade and most recently @HollensbeAmanda Braelyn.
Kelli and David are at SNO with OurBrainBank for Glioblastoma. Tonight, we present research built from patients’ and care partners’ reports of their care.
Explore: ourbrainbank.org/ourdatabank
#SNO2026 #OurBrainBankforGlioblastoma
MI Dendream retweeted
I hope more pilots come forward.
It was all a lie. A deliberate shut down to create fear and to squeeze as much money from us as possible before January.
More to come…
MI Dendream retweeted
#Illini were 8-19 from the free throw line.
Struggled to guard a ball screen
Outrebounded by eight after the first half
Had 16 turnovers
And lost by 6 at No. 16 Texas Tech.
Illinois fought hard and lost, but in my view, no need to panic. In college hoops, losses happen, and there's many months until March.
When Illinois lost to UConn last November, Illini made changes and got better.
MI Dendream retweeted
Re: j e d post# 849212
Sunday, November 08, 2026 8:54:39 PM
$nwbo @alphavestcap
1)Regarding the finalization of the RWD ECA guidance, remember that MHRA’s 2026 Business Plan says “By the end of Q4, we
will publish guidance on the use of real-world data external control arm,” so announcing it at this summit would make sense.
Whether or not this was holding back an MA decision, who knows.
assets.publishing.service.go…
2)Home
Boards
US OTC
Biotechs
NorthWest Biotherapeutics Inc (NWBO)
Followers103Posts7312Boards Moderated0Alias Born06/07/2016📷pgsd
pgsd
Re: None
Monday, November 09, 2026 4:49:00 AM
Post# of 849233
MHRA champions patient voices through new policy
The MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.
November 6, 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled a policy to enhance the role of patients and the public in forming drug and medical device regulation.
Dubbed the Patient and Public Involvement and Engagement (PPIE) Plan 2026-2030, the agency designed the policy to facilitate earlier and wider engagement with both communities and patient groups – allowing it to better consider unique patient needs while shaping its regulatory strategy.
Through this policy, the MHRA plans to inform its decisions through the lived experience of patients. This means that the regulator will consider their opinions when drafting new policies, conducting safety reviews and assessing the risk-benefit profile of a drug or device, as well as how it should govern emerging technologies like artificial intelligence (AI).
This plan builds on the MHRA’s recently announced Strategy 2030, in which the agency aims to streamline drug and device regulation, while working on making the process more patient-centric.
Through PPIE, the MHRA also hopes to hear from a more diverse group of patients by expanding its Patient and Public Community, which will guide the agency in making information about medicines more accessible for all. The MHRA first established this patient group in 2024 to unite patients, charities and patient organisations in a bid to guide MHRA decision-making.
On top of this, the regulator will also work on improving its systems, which it hopes to achieve by strengthening feedback and reporting for greater patient transparency on how their contributions influence decision-making. This will also see the MHRA focus on improving its work with the UK’s health watchdog, the National Institute for Health and Care Excellence (NICE), by diminishing duplication within its patient involvement evidence database.
Thus far, patient involvement has already benefited the MHRA, the agency says, as an advisory group of 23 patient representatives has helped to inform draft guidance and identify key priorities within the context of rare disease.
According to the MHRA’s chair, Anthony Harnden, this plan represents “a vital evolution” in the agency’s approach to patient engagement, as the healthcare landscape enters a period of rapid change.
“Patients and the public can tell us how treatments affect their everyday lives, what benefits they value most and where information needs to be clearer,” Harnden said, adding that the insights will allow the regulator to ask the right questions and make better informed regulatory decisions.
MHRA targets widespread reform
The MHRA debuts PPIE as it looks to enact wider reforms to its regulatory approach, with the agency also looking to release a Women’s Health Plan later this year.
To keep up with the changing landscape, the MHRA is also figuring out the best ways to regulate AI – both when reviewing drug and device applications, and when incorporating it into its own workflow.
This shift can also be seen within wider government initiatives. Recently, British ministers backed all 44 recommendations around AI-enabled medical devices made by its National Commission into the Regulation of AI in Healthcare.
The UK government reforms its approach as global life sciences and healthcare competition mounts – with key established players like the US and up-and-coming leaders like China increasingly attracting attention on the global stage.
Email newsletter icon
pharmaceutical-technology.co…
MI Dendream retweeted
Replying to @andrewcaravello
@andrewcaravello @alphavestcap
$NWBO #DCVaxForBraelyn A registry of off-label guesses is an admission nobody knows the target. Dendritic cells loaded with a patient's own tumor never need it. They find it, rank it and build the response. Dendritic cells do bioinformatics for a living. Phase 3 is published. #DCVax is already on FDA's own docket, FDA-2026-N-12214. Approve it.
Docket FDA-2026-N-12214 corresponds to the Food and Drug Administration's (FDA) Fit-for-Purpose Rare Disease Framework Initiative. [1, 2]Key Details of the Initiative & DocketPurpose: The initiative aims to develop a "fit-for-purpose" regulatory and development framework tailored to rare disease therapies. It seeks to align FDA review expectations with small patient populations, disease-specific realities, and attainable evidence generation. [1, 2, 3]
Public Meeting: A hybrid public meeting convened in collaboration with the Reagan-Udall Foundation for the FDA took place on October 28, 2026. [1]
Key Topics for Feedback: The FDA is asking for input on four main areas:Fit-for-purpose review based on attainable evidence, disease state, and population.
Consistency and predictability of regulatory requirements across divisions (such as CDER and CBER).
Engagement with patients, disease experts, and researchers.
Chemistry, Manufacturing, and Controls (CMC) considerations specific to rare disease therapies. [1, 2, 3]
Comment Deadline: Written or electronic comments are accepted through December 11, 2026. [1]
How to Submit CommentsYou can review existing submissions or file your own feedback via the Regulations.gov Docket for FDA-2026-N-12214 or through the Regulations.gov Comment Submission Page. [1, 2]If you're planning to submit a comment or track this policy, let me know:Are you representing a patient advocacy group, drug developer, or academic institution?
Would you like a breakdown of the specific four topic areas the FDA requested feedback on?
📷Regulations.govFit-for-purpose Rare Disease Framework InitiativeThere is no Abstract available for this docket. Verified Icon. Docket ID. FDA-2026-N-12214. Number of submissions received. 16. Th...
📷Federal Register (.gov)Federal Register :: Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and CommentsFit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments A Notice by the Food and D...
📷Federal Register (.gov)2026-21142.pdf - Federal RegisterOct 14, 2026 — For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, exce...Show allAI responses may include mistakes. For legal advice, consult a professional. Learn more
Web results
Fit-for-purpose Rare Disease Framework Initiative
📷
Regulations.gov
regulations.gov › FDA-2026-N-12214
Fit-for-purpose Rare Disease Framework Initiative Created by the Food and Drug Administration. FDA-2026-N-12214 Number. Rare Disease Framework Initiative;
Fit-for-Purpose Rare Disease Framework Initiative; Public ...
📷
Federal Register (.gov)
federalregister.gov › 2026/10/16 › fit-for-...
Oct 16, 2026 — FDA-2026-N-12214] AGENCY: developing a fit-for-purpose framework for the development and regulatory review of rare disease therapies. Monday ...
Fit-for-Purpose Rare Disease Framework Initiative
Federal Register (.gov)
public-inspection.federalreg… › ...
Oct 14, 2026 — FDA-2026-N-12214 for “Fit-For-Purpose Rare Disease Framework; Public Meeting; Request for Information and. Comments.” Received comments, those ...Read more
7 pages
FDA Rare Disease Framework: Key Implications
📷
Frier Levitt
frierlevitt.com › Insights
Oct 21, 2026 — The FDA has scheduled a public meeting for October 28, 2026, and opened a public comment docket (FDA-2026-N-12214) with a submission deadline ...
FDA Announces Rare Disease Framework Initiative, Invites ...
📷
Morgan Lewis
morganlewis.com › asprescribed › 2026/11
22 hours ago — Submitting Written Comments and Further Engagement Comments are due December 11, 2026, under Docket No. FDA-2026-N-12214. Electronic comments ...
Rare Disease Framework Initiative Public Meeting
📷
Reagan-Udall Foundation
reaganudall.org › news-and-events › events
On October 28, 2026, will convene a hybrid public meeting. FDA's Rare Disease Framework Initiative to rare disease drug development. are due December 11, 2026. ...
FDA wants feedback on new Rare Disease Framework ...
📷
Hogan Lovells Cadwalader
hlc.com › Home › Our thinking
Oct 15, 2026 — The request for information, meanwhile, will open for comments between October 28 and December 11 at Docket No. FDA-2026-N-12214.
Federal Agency Community Team (FACT) member ...
📷
Instagram · iamalsorg
10+ likes · 5 days ago
The docket number is FDA-2026-N-12214, and the public meeting is October 28, 2026, from 1 to 5 p.m. Eastern. Have you ever sent a public comment ...Read more
91 FR 65750 - Fit-for-Purpose Rare Disease Framework ...
📷
GovInfo (.gov)
govinfo.gov › app › details
Oct 16, 2026 — The hybrid public meeting will be held on October 28, 2026, from 1 to 5 p.m. Eastern Time, and will take place in-person and virtually.Read more
People also search for
FDA rare disease framework
FDA Rare Disease Day 2026
Fda rare disease framework initiative
Fda Rare Disease Day 2027
When is rare Disease Day 2026
Rare Disease Day 2026 logo
Nih rare disease day 2026
12345678910NextPage Navigation
MI Dendream retweeted
$NWBO If I had to pick the single strongest signal that NWBO approval is imminent, it’s the caliber of talent being hired. These seasoned professionals know far more than we do, have reputations to protect, and clearly see something worth betting their careers on.
MI Dendream retweeted
NWBO’s October news connects: NHSBT production support, US manufacturing restart plans, QA expertise and product tracking. My bullish take: a coordinated build-out for DCVax-L at scale while MHRA reviews. Glioblastoma patients are why this matters. $NWBO
$IBRX October was a brutal, news-free beatdown. It peaked at $10.51 on Oct 9, then fell sharply to $7.81 by Oct 26. This drop occurred on fading volume and zero fundamental changes. It was driven entirely by short-sellers hammering the stock, minor insider sales ($1.1M), and panicked retail traders exiting early.
In November, the narrative flips instantly from speculative hype to hard, unyielding data. Two massive back-to-back catalysts could realistically launch this stock into orbit:
-The Q3 Revenue Test: Wall Street expects $59.23 million in revenue. Beating this number would prove an aggressive, global commercial ramp for its FDA-approved drug, Anktiva.
-The Phase 3 QUILT-2.005 Data Launch: This is the ultimate binary event. ImmunityBio locked data for its first-line bladder cancer trial, having already teased strong interim efficacy numbers.
Flawless Phase 3 clinical data next month will force institutions to aggressively buy and trigger a violent, historic short squeeze.
MI Dendream retweeted
2026 has been a year of drowning out the $NWBO FUDpackers.
Annalisa Jenkins hired.
Powerful PSM data presented.
Spoofer Cannacord settles.
NHSBT partners up.
UK leukapheresis clinic opens.
NHS invite to keynote.
Saudi/SPIMACO MOU.
MHRA confirmation of a live MAA.
Stephen Moore imploring Right to Try DCVax.
Trump meets Braelyn.
QA leader from Roswell comes on board.
All while the loser FUD trolls spun their wheels in the same old laughable bullshit.
#DCVaxWorks #EatYerShorts





































